Tucatinib

Tucatinib (CAS No.: 937263-43-9) is a synthetic, orally bioavailable small molecule widely categorized as a targeted kinase research tool in oncology focused discovery programs, with primary relevance to ErbB receptor biology and signal transduction studies; it is characterized as a potent, reversible, ATP competitive inhibitor with high selectivity for HER2 ErbB2 over EGFR, and reported biochemical and cellular activity is in the nanomolar range, including approximately single digit nanomolar inhibitory potency against HER2 and p95 HER2, supporting its use for mechanistic interrogation of HER2 driven phosphorylation networks and downstream PI3K AKT and MAPK ERK pathway modulation in engineered and endogenous HER2 expressing cell systems; in biomedical research settings, this compound is commonly applied to define target dependency, evaluate pathway feedback and resistance phenotypes, benchmark selective HER2 blockade in comparison with broader ErbB inhibitors, and support structure activity and combination screening workflows in vitro and in animal tumor biology models, where concentrations or doses used in experiments typically depend on specific experimental designs, model characteristics, pharmacodynamic endpoints, and study objectives.